Clinical trial
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for…
NCT00385788 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00385788 |
|---|---|
| Title | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease |
| Official title | Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Disease |
| Intervention type | Drug, Procedure |
| Interventions | Gemcitabine, Fludarabine, Melphalan, Antithymocyte Globulin, Allogeneic Stem Cell Infusion, Tacrolimus, Filgrastim (G-CSF), Methotrexate |
| Enrollment | 52 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2016 |
| Completion | Aug 1, 2016 |
| First posted | Oct 11, 2006 |
| Last update posted | May 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: